Catheter Ablation Improves A-Fib Outcomes in Racial/Ethnic Minorities
In contrast, much higher event rate seen for racial and ethnic minorities randomly assigned to drug therapy in CABANA trial
In contrast, much higher event rate seen for racial and ethnic minorities randomly assigned to drug therapy in CABANA trial
Atrial Fibrillation risk was examined for patients with cancer from 2009 through 2017.
Because finerenone inhibits cardiac remodeling in preclinical models, investigators sought to examine its effect on new-onset AFF by analyzing data from the FIDELIO-DKD phase 3 trial.
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.